November 16, 2018 /

PolarisDMD: Phase 3 Clinical Trial of Edasalonexent, a Novel NF-kB Inhibitor (November 2018)

Parent Project Muscular Dystrophy by: Parent Project Muscular Dystrophy

PolarisDMD: Phase 3 Clinical Trial of Edasalonexent, a Novel NF-kB Inhibitor (November 2018)

PPMD and Catabasis hosted a webinar on November 7, 2018 to discuss the Phase 3 PolarisDMD clinical trial studying edasalonexent in Duchenne muscular dystrophy, which is enrolling boys ages 4 to 7 (up to 8th birthday) regardless of mutation type who have not been on steroids for at least 6 months.

Research & Clinical Trial Webinars,
Webinars

Join Our Mailing List

This field is for validation purposes and should be left unchanged.
BBB Accredited Charity logoCharity Navigator Four Star Charity logoNational Health Council Standards of Excellence Certification Program logo